Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inducing autoimmune disease to treat cancer.

Literature DB >> 10318881

Inducing autoimmune disease to treat cancer.

D M Pardoll.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1999 PMID： 10318881 PMCID： PMC33572 DOI： 10.1073/pnas.96.10.5340

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

× No keyword cloud information.

31 in total

1. Immunity to methylcholanthrene-induced sarcomas.

Authors: R T PREHN; J M MAIN
Journal: J Natl Cancer Inst Date: 1957-06 Impact factor: 13.506

Review 2. Unique tumor-specific antigens.

Authors: H Schreiber; P L Ward; D A Rowley; H J Stauss
Journal: Annu Rev Immunol Date: 1988 Impact factor: 28.527

3. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

Authors: W W Overwijk; D S Lee; D R Surman; K R Irvine; C E Touloukian; C C Chan; M W Carroll; B Moss; S A Rosenberg; N P Restifo
Journal: Proc Natl Acad Sci U S A Date: 1999-03-16 Impact factor: 11.205

Review 4. Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.

Authors: L J Old
Journal: Cancer Res Date: 1981-02 Impact factor: 12.701

5. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

Authors: M B Kastan; Q Zhan; W S el-Deiry; F Carrier; T Jacks; W V Walsh; B S Plunkett; B Vogelstein; A J Fornace
Journal: Cell Date: 1992-11-13 Impact factor: 41.582

6. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

Authors: A L Cox; J Skipper; Y Chen; R A Henderson; T L Darrow; J Shabanowitz; V H Engelhard; D F Hunt; C L Slingluff
Journal: Science Date: 1994-04-29 Impact factor: 47.728

7. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.

Authors: S Manici; T Sturniolo; M A Imro; J Hammer; F Sinigaglia; C Noppen; G Spagnoli; B Mazzi; M Bellone; P Dellabona; M P Protti
Journal: J Exp Med Date: 1999-03-01 Impact factor: 14.307

8. CD4 T cells and their role in antitumor immune responses.

Authors: R E Toes; F Ossendorp; R Offringa; C J Melief
Journal: J Exp Med Date: 1999-03-01 Impact factor: 14.307

9. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.

Authors: R Pieper; R E Christian; M I Gonzales; M I Nishimura; G Gupta; R E Settlage; J Shabanowitz; S A Rosenberg; D F Hunt; S L Topalian
Journal: J Exp Med Date: 1999-03-01 Impact factor: 14.307

10. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

Authors: A B Bakker; M W Schreurs; A J de Boer; Y Kawakami; S A Rosenberg; G J Adema; C G Figdor
Journal: J Exp Med Date: 1994-03-01 Impact factor: 14.307

43 in total

1. Progress in cancer vaccines by enhanced self-presentation.

Authors: S R Riddell
Journal: Proc Natl Acad Sci U S A Date: 2001-07-31 Impact factor: 11.205

2. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Authors: Willem W Overwijk; Karin E de Visser; Felicia H Tirion; Laurina A de Jong; Thijs W H Pols; Yme U van der Velden; Jasper G van den Boorn; Anna M Keller; Wim A Buurman; Marc R Theoret; Bianca Blom; Nicholas P Restifo; Ada M Kruisbeek; Robert A Kastelein; John B A G Haanen
Journal: J Immunol Date: 2006-05-01 Impact factor: 5.422

Inducing autoimmune disease to treat cancer.

1. Immunity to methylcholanthrene-induced sarcomas.

Review 2. Unique tumor-specific antigens.

3. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

Review 4. Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.

5. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

6. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

7. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.

8. CD4 T cells and their role in antitumor immune responses.

9. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.

10. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

1. Progress in cancer vaccines by enhanced self-presentation.

2. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Review 3. Rational design of peptide-based tumor vaccines.

Review 4. All in the head: obstacles for immune rejection of brain tumours.

5. Designer lymphocytes to fight cancer: a helping hand from modern molecular biology.

Review 6. Translating tumor antigens into cancer vaccines.

7. Immune balance: the development of the idea and its applications.

8. T cell homeostatic proliferation elicits effective antitumor autoimmunity.

Review 9. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic.

10. Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news?